GHK-Cu: a copper-binding tripeptide with good topical evidence and a thinner injected case

Three amino acids carrying a copper ion, present naturally in plasma and declining with age. The topical case is the strongest cosmetic-peptide evidence in this reference; the injected case is a different question with a different answer.

The copper is the active part

Established clinical use GHK is glycyl-histidyl-lysine, a tripeptide that binds copper with high affinity. That complex is what does the work: copper is a cofactor for lysyl oxidase, which cross-links collagen and elastin, and for superoxide dismutase. The peptide is essentially a delivery vehicle that hands copper to the enzymes that need it, in a form the tissue can use without the toxicity free copper would cause.

Its plasma concentration falls substantially between young adulthood and later life, which is where the anti-ageing framing comes from. The gene-expression work often cited — that GHK-Cu shifts the expression of a large number of genes toward a younger pattern — is real and is cell-culture work, and it is a long way from a clinical outcome.

Topical is where the evidence is

Established clinical use Applied to skin, GHK-Cu has controlled cosmetic studies behind it reporting improved skin density, reduced fine lines and better wound healing. That is a genuinely better evidence base than most things in this reference and is why it appears in commercial skincare. The app records topical rows for exactly that use.

Animal-only or theoretical Subcutaneous administration for systemic effect — injury healing, tissue regeneration, general anti-ageing — is a different proposition and has no controlled human trial. The app’s own regulatory string draws the line precisely: topical use is cosmetic and over-the-counter, systemic use is research only. That is the cleanest statement of the situation on this page and it comes from the app rather than from me.

The intranasal row is further out again. It exists in practice and has nothing published behind it.

Copper is the thing to watch

Off-label or community practice A peptide whose function is to carry copper, injected daily, is delivering copper. Copper accumulation is theoretical rather than demonstrated at the amounts described, and it is the reason the app puts copper levels on the monitoring list for extended high-dose use. Anyone with Wilson’s disease or another copper-handling disorder is in a different situation entirely and this is not a supplement decision for them.

Copper and zinc also compete for absorption and transport, so someone supplementing zinc heavily alongside is running two things against each other. That is worth mentioning to whoever manages their supplements.

There is no approved injectable product. Identity and purity rest with whoever made the vial, and this site names no vendor or brand. Photographic documentation is the honest assessment method for anything cosmetic, which is what the app records — the same before-and-after that makes a skin claim checkable is the one that makes a personal result readable.

The dosing rows the app records

Off-label or community practice Reproduced from the app’s reference so you can see what it holds, not as a recommendation. Which row applies to a particular person, if any, is a clinical decision this page does not make — and rows describing supraphysiological or post-cycle use are filtered out before this table is built, so what you see here is a subset.

What the app monitors alongside it

The panel below is the app’s own monitoring note for GHK-Cu, verbatim. None of the analytes it names has a page here yet.

Drawbacks and risks the app records

From the app’s own entry. The topical-versus-systemic item at the top is the whole page in one line.

• Topical vs systemic absorption debate ongoing
• SubQ injection data limited compared to topical
• Copper accumulation theoretically possible at very high doses
• Sourcing quality varies
• Mechanism fully characterized only in vitro and animal models
• Long-term systemic safety not established
• Multiple administration routes can be confusing
• Quality control varies widely by source
• Research mostly in vitro or animal models
• Not FDA approved
• Optimal dosing protocols still being established

Questions people actually ask

Does the injected form work like the topical form?

Nobody has shown that. The controlled evidence is topical and cosmetic; systemic subcutaneous use has no human trial, which is what the app’s own regulatory string says.

Is copper accumulation a real risk?

Theoretical at the amounts described rather than demonstrated, which is why the app puts copper levels on the panel for extended high-dose use. Anyone with a copper-handling disorder is in a different category.

Does it regrow hair?

Copper peptides appear in hair products and the follicle-stimulation claims come from cell and animal work. There is no controlled human trial of GHK-Cu for hair loss comparable to the ones behind the approved treatments.

Why is there no half-life in the fact box?

Because the app holds none, and for a topical the systemic half-life would not be the relevant quantity anyway.

Where the load-bearing numbers come from

Named rather than linked. Publisher URLs move, and a citation that resolves to a 404 two years from now is worse than one you can search for by name — every entry below is findable from the title and year alone.